Ondaseprol (Ondansetron)

Ondansetron, the active ingredient in Ondaseprol, is a 5-HT3 receptor antagonist presented as a  tablet for oral use. It treats and prevents nausea and vomiting associated with chemotherapy, radiotherapy, and surgery in adult and pediatric patients.

GNH USA supplies Ondaseprol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Ondansetron is used to manage nausea and vomiting by targeting the serotonergic pathways involved in emesis. - Chemotherapy‑induced nausea and vomiting: helps prevent and control acute and delayed episodes. - Radiotherapy‑induced nausea and vomiting: reduces the frequency and severity of symptoms. - Post‑operative nausea and vomiting: decreases incidence after general anesthesia.

Adverse reactions to ondansetron are generally mild to moderate, but serious events can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Diarrhoea: loose stools. - Fatigue: feeling of tiredness. - Dizziness: light‑headed sensation. - Injection site pain (if administered parenterally).

Serious or Rare Side Effects: - QT interval prolongation: may predispose to cardiac arrhythmias. - Severe hypersensitivity: rash, itching, swelling, or anaphylaxis. - Serotonin syndrome: agitation, tremor, hyperreflexia when combined with serotonergic agents. - Hepatic dysfunction: elevated liver enzymes. - Vision changes: blurred vision or visual disturbances. - Neuroleptic malignant‑like syndrome: rare but life‑threatening reaction.

When prescribing ondansetron, clinicians should consider several safety aspects. - Cardiac monitoring: patients with known QT prolongation or electrolyte imbalance should be observed. - Drug interactions: review concomitant serotonergic or QT‑prolonging medications. - Renal impairment: dose adjustment may be required in severe renal dysfunction. - Hepatic impairment: use with caution in patients with liver disease. - Pregnancy and lactation: assess risk‑benefit ratio before use. - Store at ambient temperature: keep below 25°C, protect from moisture and light, retain in original packaging.

Ondansetron may interact with several medicines, requiring vigilance.

Major Interactions (Avoid): - Amiodarone: additive risk of QT prolongation. - Cisapride: combined effect on cardiac repolarization. - Certain anti‑malarial drugs (e.g., quinidine): heightened QT prolongation risk.

Moderate Interactions (Monitor Closely): - Serotonergic agents (SSRIs, SNRIs, MAOIs): potential for serotonin syndrome. - Antifungal azoles (ketoconazole, fluconazole): may increase ondansetron plasma levels. - Macrolide antibiotics (erythromycin, clarithromycin): modest QT effect. - Calcium channel blockers (diltiazem, verapamil): may raise drug concentrations.